Clinical stabilisation in patient with rapidly evolving severe multiple sclerosis – case report Case report

Abstract

Multiple sclerosis is chronic, demyelinating disease of central nervous system for which 2.500 million people are affected in the world. Main treatment goal for treatment of multiple sclerosis is to inhibit disease activity described as achieving NEDA – no evidence of disease activity. In recent years many clinical trials were conducted with new molecules and a few medications were registered for the treatment of remitting-relapsing multiple sclerosis.

Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. Ocrelizumab is associated with lower rates of disease activity and progression than interferon β-1a over a period of 96 weeks. In this article the case of patient with rapidly evolving MS with clinical stabilisation after treatment with ocrelizumab is presented.